Global brokerage firms have a target price in the range of Rs 535-560 on Sun Pharma which translates into an upside of 22-28 percent return in the next 12 months.

Sun Pharma Q3 preview: Analysts expect healthy growth in profit, revenue on US business

Emkay and Motilal Oswal see 17 percent year-on-year growth in bottomline while Prabhudas Lilladher expects profit to grow 137 percent and ICICI Securities expects 178 percent

Sun Pharma Q3 PAT seen up 17% YoY to Rs. 1,027.4 cr: Sharekhan

Net Sales are expected to increase by 6 percent Y-o-Y (up 1.6 percent Q-o-Q) to Rs. 7,052 crore, according to Sharekhan.

Sun Pharma Q3 PAT seen up 178.4% YoY to Rs. 1,017.1 cr: ICICI Direct

Net Sales are expected to increase by 14.4 percent Y-o-Y (up 9.7 percent Q-o-Q) to Rs. 7,609 crore, according to ICICI Direct.

Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila

For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.

Sun Pharma Q2 profit likely to get a boost from healthy US business, Halol resolution

Brokerages expect profit to be around Rs 950-1,087 crore.

Sun Pharma Q2 PAT seen up 17.1% YoY to Rs. 1,070 cr: HDFC Securities

Net Sales are expected to increase by 12.5 percent Y-o-Y (up 3.6 percent Q-o-Q) to Rs. 7,480 crore, according to HDFC Securities.

Sun Pharma Q2 PAT seen up 9.8% YoY to Rs. 1,100.1 cr: Sharekhan

Net Sales are expected to increase by 13.7 percent Y-o-Y (up 4.7 percent Q-o-Q) to Rs. 7,560 crore, according to Sharekhan.

India Inc poised for 10% earnings growth in Q2; IT, consumer & metals may see strong results

Revenue is expected to grow robustly at more than 20 percent but due to margin headwinds and extended provisioning requirements of corporate lenders, bottom-line improvement is slow

Sun Pharma Q2 PAT seen up 5.8% YoY to Rs. 964.8 cr: ICICI Direct

Net Sales are expected to increase by 15.8 percent Y-o-Y (up 6.6 percent Q-o-Q) to Rs. 7,698.1 crore, according to ICICI Direct.

Sun Pharma Q1 review: All eyes on the speciality business

We continue to like the strong domestic business of Sun and the niche that it is trying to create with speciality in the US.

Analysts turn mixed on Sun Pharma despite Q1 nos beat estimates; CLSA ups target to Rs 750

CLSA and HSBC remained positive on the stock but Citi maintained its Neutral call and Prabhudas Lilladher Reduce rating on Sun Pharma.

Sun Pharmaceuticals Q1 PAT seen up 68.7% YoY to Rs. 886.9 cr: Kotak

Net Sales are expected to increase by 14.3 percent Y-o-Y (up 1.7 percent Q-o-Q) to Rs. 7,096.3 crore, according to Kotak.

Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz

"For the first time after six consecutive quarters, the pharma companies under our coverage will report double digit YoY growth of 13 percent in revenues,” said HDFC Securities

Sun Pharma Q4 PAT may dip 29.8% YoY to Rs. 944.4 cr: KR Choksey

Net Sales are expected to decrease by 2.4 percent Y-o-Y (up 1 percent Q-o-Q) to Rs. 6,664.1 crore, according to KR Choksey.

Sun Pharma Q4 PAT may dip 18.1% YoY to Rs. 1,000 cr: HDFC Securities

Net Sales are expected to decrease by 5.1 percent Y-o-Y (up 1.8 percent Q-o-Q) to Rs. 6,780 crore, according to HDFC Securities.

Sun Pharma Q4 PAT may dip 39.1% YoY to Rs. 745.2 cr: Edelweiss

Net Sales are expected to decrease by 6.4 percent Y-o-Y (up 0.4 percent Q-o-Q) to Rs. 6,676.9 crore, according to Edelweiss.

Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key

Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.

Analysts expect Sun Pharma to fall up to 25% post Q3 earnings, await Halol resolution

All brokerage houses barring Motilal Oswal highlighted in this article are having Reduce to Hold rating and expect the stock to fall up to 25 percent.

Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key

As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.

Sun Pharma Q2 profit seen down 64% to Rs 802 cr lower revenue, operating income

Revenue during the quarter is seen declining 17 percent to Rs 6,861 crore compared with Rs 8,265 crore in same quarter last fiscal, according to average of estimates of analysts polled by CNBC-TV18.

Sun Pharmaceuticals Q2 PAT may dip 62.3% YoY to Rs. 848.7 cr: Kotak

Net Sales are expected to decrease by 15.2 percent Y-o-Y (up 12.8 percent Q-o-Q) to Rs. 7006.1 crore, according to Kotak.

Targeting 15% growth for FY18, export will pick up sizeably: Omkar Speciality

In an interview to CNBC-TV18, Pravin Herlekar, CMD of Omkar Speciality Chemicals discussed the company's Q1 performance.

Sun Pharma Q1 profit seen down 44% to Rs 1,144 cr on pricing pressure in US

Operating profit is likely to crash 40 percent to Rs 1,744.5 crore and margin may contract 1,080 basis points to 24.6 percent compared with same quarter last year.

Sun Pharma Q1 PAT may dip 24.69% YoY to Rs 1713.2 cr: KR Choksey

Net Sales are expected to decrease by 2.39 percent Q-o-Q (down 16.79 percent Y-o-Y) to Rs 6662 crore, according to KR Choksey. Sun Pharma to report net profit at 1713.2 crore down 24.69% year-on-year.